Feb 5, 2018 Update



Saw this article on Yahoo chat site .
Maybe pushed by Yahoo as article with news next day .

GW Pharmaceuticals Isn’t a Cannabis Stock – and 4 Other Things Its CEO Wants You to Know
What you’ll want to know from GW Pharmaceuticals CEO Justin Gover’s comments this week at the Morgan Stanley conference.
Keith Speights
Sep 12, 2019 at 7:30AM
Don’t call GW Pharmaceuticals (NASDAQ:GWPH) a cannabis stock around the company’s CEO, Justin Gover. He said at the Morgan Stanley Global Healthcare Conference on Wednesday that it’s “frustrating” when GW is listed among cannabis stocks. Gover stated emphatically, “We’re a biotech company.”

Of course, GW Pharmaceuticals is often labeled a cannabis stock or marijuana stock, and for a good reason: The company focuses on developing cannabis-derived drugs. But Gover’s point is that GW’s business and regulatory environment is much different than that of most companies whose stocks are grouped in the cannabis stock category.

Gover didn’t vent for too long at the Morgan Stanley conference, though. Here are four other things he said that investors interested in GW Pharmaceuticals will want to know.

Five test tubes in a rack with a cannabis leaf on top of the rack.

  1. Expect strong – but slowing – U.S. growth for Epidiolex
    GW’s cannabidiol (CBD) drug Epidiolex has gotten off to a roaring start in the U.S. The company reported that sales for Epidiolex totaled $68.4 million in the second quarter, more than double the level achieved in the previous quarter. Over 12,000 patients have received Epidiolex since GW launched the drug in the U.S. market in late 2018.

Gover said that he expects sustained strong sales growth for Epidiolex in treating Dravet syndrome and Lennox-Gastaut syndrome (LGS). However, he cautioned that the rate of growth will cool down somewhat.

There was a tremendous pent-up demand for Epidiolex when it first hit the U.S. market. Gover said that the initial wave of patients is past and that GW is in “a different phase” now. But he doesn’t think that sales of Epidiolex will be hurt by patients using over-the-counter CBD products because insurers will only pay for FDA-approved medications.

  1. Optimistic about European launch of Epydiolex
    There has been good news and bad news with respect to GW Pharmaceuticals’ plans to launch Epidyolex in Europe. (Note: The European brand name is spelled slightly differently from the drug’s U.S. brand name.) First, the good news: The Committee for Medicinal Products for Human Use (CHMP) recommended that Epidyolex be approved by the European Medicines Agency (EMA). The bad news, however, was that the United Kingdom’s National Institute for Health and Care Excellence (NICE) thinks that the price tag for the drug is too high.

Gover stated that he’s optimistic that NICE will recommend the use of Epidyolex in the U.K. when it announces its final guidance later this year. He said that the company plans to launch the drug in France, Germany, and the U.K. in quick succession, assuming it wins EMA approval as expected. GW anticipates rolling out Epidyolex in Italy and Spain around the middle of 2020, followed by launches in other European countries.

The market dynamics in Europe are different than the U.S. Gover said that European reimbursement systems make a large influx of patients at the outset less likely. He thinks that there will be a “more gradual adoption in Europe.”

  1. More indications, more formulations on the way
    The oral solution of Epidiolex in treating Dravet syndrome and LGS is just the beginning. Gover said that GW fully expects more indications will be approved for the drug. He also said the company is developing new formulations for Epidiolex, including capsules.

GW could win FDA approval for Epidiolex in treating tuberous sclerosis complex (TSC) as soon as next year. Gover said that an approval for the drug in TSC on top of its current approved indications could cause physicians to view Epidiolex as “a broad spectrum anti-seizure medication.”

The company is also conducting a phase 3 clinical study evaluating Epidiolex in treating rare genetic neurological disorder Rett syndrome. Gover said that it will probably be a couple of years before results from this study are available.

  1. GW Pharmaceuticals isn’t a one-trick pony
    While investors are rightfully focused on the potential for Epidiolex, Gover stated that GW Pharmaceuticals “isn’t a one-product company.” Sativex is already approved in multiple countries outside of the U.S. in treating multiple sclerosis spasticity. Gover said that the drug is “one to watch” as GW pursues obtaining FDA approval as well.

He stated that the company will announce more details on its plans for Sativex next year. A clinical study is cranking up to gather additional data needed to support a U.S. filing for the drug.

In addition, GW’s pipeline includes several other cannabinoids in development. Gover said that a “golden era for cannabinoid science” could be underway. And he wants investors to know that GW Pharmaceuticals has a unique role in this new era.

Here’s The Marijuana Stock You’ve Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.


Topped again @ 118$ not sure why its dropping so much ?
Below from Yahoo finance looked good news. !!!
Came through to phone today dated yesterday 24th September .

GW Pharmaceuticals plc GWPH announced that the European Commission (EC) has approved its anti- epileptic drug Epidyolex as an adjunct treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in conjunction with clobazam for patients aged two years or older.

The nod makes Epidyolex (cannabidiol oral solution) the first plant-derived cannabinoid prescription medicine to be approved by the European Medicines Agency (EMA). The drug is also the first and the only EMA-approved cannabidiol (CBD) medicine approved to treat LGS and Dravet syndrome, two severe and life-threatening forms of childhood-onset epilepsy.

In July 2019, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion on Epidyolex, recommending its marketing authorization application for the given indication.

Epidyolex is marketed as Epidiolex in the United States for treating seizures associated with LGS or Dravet syndrome in patients aged two years and above.

The EU approval was based on data from four phase III studies, which evaluated Epidyolex in 714 patients with either LGS or Dravet syndrome. When added to other anti-epileptic therapies, Epidyolex significantly reduced the frequency of seizures in the given patient population.

Shares of GW Pharmaceuticals have rallied 29.9% so far this year compared the industry’s increase of 17.4%.

Epidiolex was approved in the United States in June 2018. The product became the first cannabis-derived medicine to gain an approval from the FDA for the treatment of LGS and Dravet syndrome in patients aged two years or older.

Epidiolex generated sales of $101.9 million in the first half of 2019. The drug has seen a strong uptake in sales and new patient enrollments since its launch.

In May this year, GW Pharmaceuticals announced positive top-line results from the phase III study evaluating Epidiolex for treating seizures associated with tuberous sclerosis complex (TSC). A supplemental new drug application for the same is expected to be filed in the fourth quarter of 2019.

We remind investors that the marijuana industry has a solid potential, especially after its legalization for recreational and medicinal use. Further, legalization of cannabis is likely to drive its commercial distribution and boost growth of companies operating in this space. Apart from GW Pharmaceuticals, companies, such as CannTrust Holdings Inc. CTST, Cronos Group Inc. CRON and Canopy Growth Corp. CGC are all discovering, developing and manufacturing drugs from cannabis for various recreational and medicinal purposes.

Zacks Rank

GW Pharmaceuticals currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank


Jersey … noticed big price fall ( failed limits last week )
Put what i thought was a cheeky 108$ limit ( whole order ) early Wednesday 2nd T birthday lol …
Strait trough @ 107.6 … on way to 105.8 … finished 109.
To buy fx $ 1.2262.

Sold 70% of them back @ 110$ next day Thursday i am away and can not fund acc.
fx…1.233 … sell.
Wish i had waited sold that 30% back @ 120$ today Friday 4th October .


Falling back to last months low prices today Thursday 6th November.
This news from Wednesday 5th only thing i can find .
Appears RNS late on the Tuesday .
Had the notion to place a sale ( W ) on the Monday as price was nearing 143 $
Hindsight should of taken that recent high .

GW Pharmaceuticals Reports Q3 Sales Beat, Stock Falls
Brett Hershman
BenzingaNovember 5, 2019

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are down after the company released its third-quarter earnings report Tuesday afternoon.

Third-quarter earnings came in at a loss of 4 cents per share, which may not compare to estimates that called for an 87-cent loss. Sales came in at $90.971 million, beating estimates by $5.06 million.

Net sales for the company’s lead product, Epidiolex, came in at $86.1 million.

View more earnings on GWPH

See Also: GW Pharma’s CBD Seizure Drug Epidiolex Approved In Europe As Adjunctive Therapy

“In this first year of launch, we are pleased to report continued Epidiolex revenue growth in the US. Receptivity to the introduction of this breakthrough treatment continues to be highly encouraging as a result of positive physician and patient experiences as well as strong payer coverage,” CEO Justin Gover said. “We see significant opportunity for the short, medium and long term and believe that all the fundamentals are in place to make Epidiolex a very successful brand. We can expect to see additional momentum from Europe as well as the launch of the Tuberous Sclerosis indication during 2020.

"On top of this, GW is ideally placed to consolidate its leadership in cannabinoid science through advancing several mid and late stage pipeline programs in the months ahead.”

GW Pharmaceuticals shares fell more than 12% in after-hours trading. The stock closed the regular session at $134.75 per share.


Patience… would not lift for the Jersey low buy of 107$ yesterday … it did today @ 3pm ( 30 min after there opening… maybe ? )
Ex rate better for me @…1.28… 1.22… 3rd October


Interesting how price fell to recent lows Friday as news today Monday 11th Nov that two drugs accepted by UK regulators . Maybe as they have offered the NHS a lower price ?
Money would of known this news in advance.
Below an article from Friday advising hold it … appears sales might be seeing a plateau .

Why Investors Should Remain Bullish On GW Pharmaceuticals (GWPH)
NASDAQ: GWPH | GW Pharmaceuticals Plc News, Ratings, and Charts
GWPH – GW Pharmaceuticals (GWPH) reported third-quarter earnings after the close of trade on Tuesday.

By Aaron Missere
Nov 8, 2019

Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from!

Your Email Address…
GW Pharmaceuticals (GWPH - Get Rating) reported third-quarter earnings after the close of trade on Tuesday. The company posted a net loss of $13.8 million for the quarter, which is a significant improvement from last tear in the same quarter last year when they lost $79.9 million.

They also posted better than expected sales numbers for their flagship product Epidiolex, coming in at $86.1 million for the quarter, which beat analysts estimates of $85.2.

Yet, even with these positive numbers, shares of GWPH have dropped dramatically, from about $135 to $110. This reason given was because of fears that Epidiolex sales could plateau over the next several quarters.

However, some analysts on Wall Street don’t agree with this theory.

9 “Must Own” Growth Stocks For 2019

After their earnings release, Bank of America analyst Tazeen Ahmad reiterated a Buy rating for the stock and $218 price target. GW Pharmaceutical’s U.S. Epidiolex sales climbed 26% from the previous quarter and came in ahead of estimates, Ahmad said in a note. Continued patient adds and new doctor prescriptions were behind the strength.

After having penetrated the high patient concentration centers of demand during early launch, Ahmad said the company is likely to turn its focus on an additional tier of 1,000 prescribers, which present a meaningful growth opportunity going forward.

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on the stock but lowered the price target from $229 to $174. Duncan said GW Pharmaceutical’s decision to deploy resources in 2020 to target long-term care segment could be a capital-efficient growth driver for Epidiolex adoption.

We also heard positive sentiment from the GW Pharmaceuticals CEO Justin Grover regarding the progress Epidiolex has accomplished so far “In this first year of launch, we are pleased to report continued Epidiolex revenue growth in the U.S. Receptivity to the introduction of this breakthrough treatment continues to be highly encouraging as a result of positive physician and patient experiences as well as strong payer coverage.”

In addition, GW Pharmaceuticals has been working on releasing Epidiolex in Europe and in September the company said that it received European Commission approval and that “commercialization is underway in France and Germany.”

As GW Pharmaceuticals continues to expand the reach of Epidiolex and break into new markets their revenues should increase. They have spent considerable capital on developing the drug and the barrier for entry remains extremely high, so competition should be almost non-existent.

With valuations taking a haircut after this recent earnings report, it’s going to be hard for investors to continue to sell this stock if they keep delivering better than expected numbers. We feel that once GW Pharmaceuticals shows increased profitability, investors will have a more favorable viewpoint of the company.

GW Pharmaceuticals remains a top stock for us to watch and now that share price has fallen, it could be a strong buying opportunity.

GWPH shares were trading at $110.68 per share on Friday afternoon, up $1.64 (+1.50%). Year-to-date, GWPH has gained 13.65%, versus a 25.03% rise in the benchmark S&P 500 index during the same period.

About the Author: Aaron Missere

Aaron is an experienced investor who is also the CEO of Departures Capital. His primary focus is on the cannabis industry. He also hosts a weekly show on YouTube about marijuana stocks. Learn more about Aaron’s background, along with links to his most recent articles. More…


Topped up 106 $ fx rate 1.2876 … on the 8th above 1.2806.
So fx rate slightly better if higher is better.
If log is correct about 20 shares down since conversion.


Bought some at 107 for a trade.


Hi Lastemporer.
Is this your first buy here , think i have seen you somewhere on the site.
what brought it to your attention .
Its one of my best ever buys :grinning:


Owned it when it was GWP on AIM and sold out back at $150 last year,

Always looked like a good trading stock, buy below 110 and sell over 120 +


Yes it is pretty consistent and keeps doing that .
To be honest i only started doing as i want to move holding from one broker to another but noticed you can make.
Know any other like it .


Some other bouncy US stocks are:



Thank you … they are all high tec stocks… cloud tec ect